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Is Increased Hepatitis C Virus
Case-Finding Combined With Current
or 8-Week to 12-Week Direct-Acting
Antiviral Therapy Cost-Effective in UK
Prisons? A Prevention Benefit Analysis
Natasha K. Martin,1,2 Peter Vickerman,2 Iain F. Brew,3 Joan Williamson,3 Alec Miners,4 William L. Irving,5 Sushma Saksena,6
Sharon J. Hutchinson,7 Sema Mandal,8 Eamonn O’Moore,8 and Matthew Hickman2
Prisoners have a high prevalence of hepatitis C virus (HCV), but case-ﬁnding may not have been cost-effective because treat-
ment often exceeded average prison stay combined with a lack of continuity of care. We assessed the cost-effectiveness of
increased HCV case-ﬁnding and treatment in UK prisons using short-course therapies. A dynamic HCV transmission model
assesses the cost-effectiveness of doubling HCV case-ﬁnding (achieved through introducing opt-out HCV testing in UK pilot
prisons) and increasing treatment in UK prisons compared to status quo voluntary risk-based testing (6% prison entrants/
year), using currently recommended therapies (8-24 weeks) or interferon (IFN)-free direct-acting antivirals (DAAs; 8-12
weeks, 95% sustained virological response, £3300/week). Costs (British pounds, £) and health utilities (quality-adjusted life
years) were used to calculate mean incremental cost-effectiveness ratios (ICERs). We assumed 56% referral and 2.5%/25% of
referred people who inject drugs (PWID)/ex-PWID treated within 2 months of diagnosis in prison. PWID and ex-PWID or
non-PWID are in prison an average 4 and 8 months, respectively. Doubling prison testing rates with existing treatments pro-
duces a mean ICER of £19,850/quality-adjusted life years gained compared to current testing/treatment and is 45% likely to
be cost-effective under a £20,000 willingness-to-pay threshold. Switching to 8-week to 12-week IFN-free DAAs in prisons
could increase cost-effectiveness (ICER £15,090/quality-adjusted life years gained). Excluding prevention beneﬁt decreases
cost-effectiveness. If >10% referred PWID are treated in prison (2.5% base case), either treatment could be highly cost-
effective (ICER<£13,000). HCV case-ﬁnding and IFN-free DAAs could be highly cost-effective if DAA cost is 10% lower
or with 8 weeks’ duration. Conclusions: Increased HCV testing in UK prisons (such as through opt-out testing) is borderline
cost-effective compared to status quo voluntary risk-based testing under a £20,000 willingness to pay with current treatments
but likely to be cost-effective if short-course IFN-free DAAs are used and could be highly cost-effective if PWID treatment
rates were increased. (HEPATOLOGY 2016;63:1796-1808)
Hepatitis C virus (HCV) is a blood-borne viruswhich can result in cirrhosis, liver failure,hepatocellular carcinoma, and death. In most developed country settings the majority of transmissionoccurs among people who inject drugs (PWID). In theUnited Kingdom, >90% of ongoing transmission occurs
Abbreviations: CI, conﬁdence interval; DAA, direct-acting antiviral; HCV, hepatitis c virus; ICER, incremental cost-effectiveness ratio; IFN-free,
interferon-free; pegIFN, pegylated interferon; PWID, people who inject drugs; QALY, quality adjusted life-year; RBV, ribavirin; SVR, sustained viro-
logical response; WTP, willingness to pay.
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among PWID, and >80% of chronic HCV infection is
among current or ex-PWID.(1) Previous treatments with
pegylated interferon and ribavirin (pegIFN1RBV) were
long (24-48 weeks), were poorly tolerated, and cured
roughly half of individuals. The advent of new short-
course, better-tolerated, and highly effective HCV treat-
ments which can cure >80% of individuals makes iden-
tifying those who are chronically infected an urgent
priority.(2) HCV case-ﬁnding in specialist drug clinics
and primary care is recommended and cost-effective,
especially with increased treatment rates.(3,4)
Although there are high numbers and proportions of
PWID in prison, testing rates are relatively low (6%
prison entrants were tested for HCV in England in
2013(5)). Previous analyses suggested that the cost-
effectiveness of increasing HCV case-ﬁnding in UK
prisons was conditional on a high level of continuity of
care between prison and community and unlikely to be
cost-effective in the absence of any continuity.(3) This
was because of the conﬂict between short incarceration
times for PWID (estimated average 4 months in Eng-
land) and long treatment durations (24-48 weeks)
required with pegIFN1RBV treatment.
The current standard of care in UK prisons is volun-
tary HCV testing offered to prisoners who consider
themselves at risk, leading to approximately 6% of
prison entrants tested per year. In 2014, opt-out test-
ing for blood-borne viruses (HCV, hepatitis B virus,
and human immunodeﬁciency virus) was introduced in
selected prisons in England,(6) which doubled the
numbers of HCV tests in these pilot prisons. Hence,
this opt-out program is likely to increase the numbers
tested and initiated onto HCV treatment from within
the prison setting. However, suboptimal treatment
delivery (roughly half of HCV-infected cases are
referred to specialist care, with one-quarter of those
referred initiating treatment,(7) of which many will
have interrupted treatment due to prison release) may
limit the beneﬁt of testing interventions. Shorter-
duration (8-12 weeks) interferon (IFN)-free direct-
acting antiviral (DAA) therapy with high sustained
virological response (SVR) rates (>90%)(2) could allow
more to successfully complete treatment within their
prison stay.
We assessed the cost-effectiveness of increased HCV
testing and treatment rates in English prisons (such as
through opt-out programs, which doubled testing in
UK pilot prisons) compared to status quo testing rates
combined with currently available HCV treatments or
future 8-week to 12-week IFN-free DAA therapy,
including individual and prevention beneﬁts.
Materials and Methods
MATHEMATICAL MODEL
We adapted a dynamic model of incarceration and
HCV transmission among PWID in England.(3,4) Full
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details of the model structure and calibration can be
found in previous publications(3,4) and the Supporting
Information. Overall, the model tracks incarceration,
initiation and cessation of injecting, HCV transmission
among PWID only (in both prison and the community;
imprisoned PWID can only transmit to other prisoners)
and HCV testing and treatment through various set-
tings present in the United Kingdom (prison, addiction
services, general population, and other). The model is
dynamic in that a PWID’s risk of acquiring HCV is
proportional to the setting-speciﬁc HCV prevalence
(prison, community), which can change over time. The
model simulates the background rate of testing and
treatment occurring in the community and prison, such
that individuals can be identiﬁed in either setting.
The model includes stratiﬁcation by injecting state
(never PWID/PWID/former PWID), incarceration
status (never/currently/formerly), contact with addic-
tion services (in contact/not in contact), age (15-19,
20-24, 30-54, 55-64, 65-74, 751), and HCV infection
and disease progression (never infected, spontaneously
cleared, mild HCV, moderate HCV, compensated cir-
rhosis, decompensated cirrhosis, hepatocellular carci-
noma, liver transplant, posttransplant). HCV disease
stages are further subdivided into undiagnosed or diag-
nosed, where those who are diagnosed can either be
lost to follow-up, in referral, on antiviral treatment,
achieved SVR, or non-SVR. Because no data are avail-
able on continuity of care between the prison and com-
munity, we assumed that those who are in referral or on
treatment are lost-to follow-up when entering or leav-
ing prison, in line with our previous analyses.(3,4)
We include updated treatment SVR and durations
with new and upcoming IFN-free DAA therapies as
well as progression for those in the cirrhosis SVR stage
(at reduced rates compared to non-SVR), in accord-
ance with recent data.
MODEL CALIBRATION
We performed a probabilistic uncertainty analysis
where 1000 parameter sets were sampled from each
parameter uncertainty distribution in Table 1. For each
parameter set, the model was calibrated to UK epide-
miological data on incarceration, injecting drug use,
HCV prevalence, and diagnosis. Further calibration
details can be found in our previous publications(3,4)
and the Supporting Information. After calibration, for
each of the 1000 parameter sets, the model was used to
simulate the baseline and intervention scenarios.
BASELINE
The baseline scenario assumes status quo rates of
HCV voluntary risk-based testing (mean 6% of prison
entrants tested annually) and treatment with current
(provisionally approved by the National Institute for
Health and Care Excellence) therapies.(8,9) The current
therapies modeled are as follows: genotype 1: sofosbuvir/
ledipasvir for genotype 1 patients without cirrhosis (8
weeks) and with cirrhosis (12 weeks); genotype 2:
pegIFN1RBV for 24 weeks; genotype 3: pegIFN1
RBV for 24 weeks for patients without cirrhosis and
sofosbuvir1 pegIFN1RBV for 12 weeks for patients
with cirrhosis; genotype 4: sofosbuvir/ledipasvir for 12
weeks. Based on an estimated genotype distribution of
50% genotype 1/4, 5% genotype 2, and 45% genotype 3,
the mean average SVR for this scenario is 87%.
INTERVENTION
We examined a doubling of HCV testing in prison
(to a mean 12% of prison entrants per year) due to a
scale-up of opt-out testing (as achieved during phase
1(6)) with various treatment scenarios:
1. Status quo treatments: Doubling of HCV testing
in prison with current treatments (as in the base-
line, mean average SVR 87%) in prison and the
community
2. 8-week to 12-week IFN-free DAAs: Doubling of
HCV testing in prison with 8-week to 12-week
IFN-free DAAs with 95% SVR in prison (8
weeks G1 patients without cirrhosis, 12 weeks all
others) and current treatments (as in the baseline)
in the community
3. Treatments as in (1) and (2) but with treatment
scale-up for PWID: The scenarios above (status
quo, 8-week to 12-week IFN-free DAAs) but
with varied levels of HCV treatment for PWID
in prison (up to 25% after referral compared with
a mean of 2.5% at base case)
COST-EFFECTIVENESS
METHODS
We performed our analysis from the UK National
Health Service perspective as HCV testing and treat-
ment are paid for by the National Health Service.
Costs (in 2014 British pounds, £1 5 $1.50) and health
utilities (in quality adjusted life-years [QALYs]) were
attached to each model state and discounted at 3.5%
per year per the National Institute for Health and Care
MARTIN ET AL. HEPATOLOGY, June 2016
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TABLE 1. Model Parameters
Mean value Distribution Reference
Transition probabilities per year (all probabilities converted to instantaneous rates)
Mild to moderate 0.025 Beta (a 5 38.0859, b 5 1485.3516) (19)
Moderate to CC 0.037 Beta (a 5 26.905, b 5 700.2582) (19)
CC to DC 0.039 Beta (a 5 14.6168, b 5 360.1732) (19)
CC/DC to HCC 0.014 Beta (a 5 1.9326, b 5 136.1074) (19)
CC SVR to DC (relative risk of non-SVR) 0.07 Log normal (95% CI 0.03-0.20) (20,21)
CC/DC SVR to HCC (relative risk of non-SVR) 0.23 Log normal (95% CI 0.16-0.35) (22)
DC/HCC to LT 0.03 Beta (a 5 6.5256, b 5 210.9945) (19)
DC to death 0.13 Beta (a 5 147.03, b 5 983.97) (19)
HCC to death 0.43 Beta (a 5 117.1033, b 5 155.23) (19)
LT to death 0.21 Beta (a 5 16.2762, b 5 61.2294) (19)
Posttransplant to death 0.057 Beta (a 5 22.9017, b 5 378.8825) (19)
Health state utilities/disutilities per year
Ex-PWID age 15-19
Uninfected 0.94 (38)
Mild 0.77 Beta (a 5 521.2375, b 5 155.6943) (19,39)
Moderate 0.66 Beta (a 5 168.2461, b 5 86.6723) (19,39)
Cirrhosis 0.55 Beta (a 5 47.1021, b 5 38.5381) (19,39)
DC 0.45 Beta (a 5 123.75, b 5 151.25) (19,39)
HCC 0.45 Beta (a 5 123.75, b 5 151.25) (19,39)
LT 0.45 Beta (a 5 123.75, b 5 151.25) (19,39)
Posttransplant 0.67 Beta (a 5 59.2548, b 5 29.1852) (39,40)
Treatment IFN-containing, decrement 0.11 (19,39)
Treatment IFN-free, decrement 0.06 (8)
Mild SVR 0.82 Beta (a 5 65.8678, b 5 14.4588) (19,39)
Moderate SVR 0.72 Beta (a 5 58.0608, b 5 22.5792) (19,34,39)
Cirrhosis SVR 0.61 Beta (a 5 58.0476, b 5 37.1124) (40)
PWID age 15-19
Uninfected 0.74 Uniform (0.67-0.8) (41)
HCV disease states As in ex-PWID but reduced by PropPWID* Assumed
Disutility with age
20-24 0 (38)
25-29 0.005 (38)
30-54 0.049 (38)
55-64 0.14 (38)
65-74 0.16 (38)
751 0.21 (38)
Costs (£ per year, except where noted)
Mild diagnosed 178 PPI† 3 Gamma (j 5 25.6995, u 5 5.3698) (19,39)
Moderate diagnosed 925 PPI 3 Gamma (j 5 88.8502, u 5 8.0698) (19,39)
Cirrhosis diagnosed 1468 PPI 3 Gamma (j 5 24.2342, u 5 46.9584) (19,39)
DC 11,765 PPI 3 Gamma (j 5 36.0249, u 5 253.1582) (19,39)
HCC 10,484 PPI 3 Gamma (j 5 18.1081, u 5 448.8045) (19)
LT (per transplant) 35,256 PPI 3 Gamma (j 5 89.7536, u 5 304.5004) (19)
Cost of care in year of LT 12,201 PPI 3 Gamma (j 5 13.7788, u 5 686.4168) (19)
Posttransplant 1787 PPI 3 Gamma (j 5 15.2189, u 5 91.0053) (19)
Mild SVR 334 PPI 3 Gamma (j 5 28.8141, u 5 8.9887) (19)
Moderate SVR 925 PPI 3 Gamma (j 5 88.8502, u 5 8.0698) (19)
Cirrhosis SVR 1468 PPI 3 Gamma (j 5 24.2342, u 5 46.9584) (19)
Undiagnosed states 0
Drug costs, per week§
pegIFN1RBV 228 (24)
SOF1PR 3143 (24)
SOF/ledipasvir 3248 NHS list price
“Future” IFN-free DAAs 3300
Treatment delivery, per week§
Ex-PWID 90 (19)
PWID (proportion ex-PWID cost) 120% (3,23)
Testing costs in community# 121 Uniform 6 50% (3,42)
Testing costs in prison# 151 Uniform 6 60% (3,42)
PCR RNA test (if antibody-positive) 78 Uniform 6 20% (3,42)
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Excellence guidelines. We used a 100-year time hori-
zon to accrue both individual and population beneﬁts.
We calculated the mean incremental cost-effectiveness
ratio (ICER) by dividing the difference in mean costs
by the difference in mean QALYs between the inter-
vention and its comparator. We performed an incre-
mental analysis where the ICERs are calculated for
each intervention after ranking the alternatives from
least to most costly. We determined cost-effectiveness
using UK willingness-to-pay (WTP) thresholds of
£20,000 and £30,000 per QALY gained and denoted
an intervention as highly cost-effective using a WTP
TABLE 1. Continued
Mean value Distribution Reference
Testing and treatment parameters
Proportion PWID diagnosed (initial) 50% (5)
Proportion PWID treated (initial) 0% Assumption
Proportion ex-PWID diagnosed (initial) 30% Uniform (24%-36%) Assumption (14)
Proportion of diagnosed ex-PWID treated (initial) 10% Uniform (5%-15%) (43)
HCV genotype (proportion)§
G1 45% (5)
G2 5%
G3 45%
G4 5%
SVR§
IFN/RBV G2/G3 mild/mod 0.8 Uniform (0.75-0.85) (44,45)
IFN/RBV G2 cirrhosis 0.6 75% reduction from mild to moderate (46)
Harvoni G1/G4 noncirrhosis 0.93 Uniform (0.9-0.96) (47)
Harvoni G1/G4 cirrhosis 0.94 Triangular (min 0.9, max 0.99) (48)
SOF1PR G3 cirrhosis 0.83 Triangular (min 0.52, max 0.98) (49)
Future IFN-free DAAs 0.95 Assumption
Antiviral treatment duration (weeks)§
Harvoni G1 noncirrhosis 8 (9)
Harvoni G1 cirrhosis, G4 12 (9)
pegIFN/RBV G2 24 (44)
pegIFN/RBV G3 noncirrhosis 24 (44)
SOF1PR G3 cirrhosis 12 (8)
Proportion referred
Prison 56% Uniform (41%-70%) (15)
Community 86% Uniform (80%-90%)
Proportion referred who initiate treatment within 1 year (excl. prison)
Ex-PWID 50% Uniform (40%-60%) (35,50)
PWID 5% Uniform (1%-10%) Assumption (51)
Treatment initiation rate after first year in referral (excl. prison) per year
Ex-PWID 10% Uniform (5%-15%) Assumption
PWID 3% Uniform (1%-5%) Assumption (51)
Proportion referred who initiate treatment in prison within 2 months
Ex-PWID 25% Uniform (20%-30%) (6,7)
PWID 2.5% Uniform (0%-5%) Assumption (51)
Yield (proportion tests antibody-positive)
General 2.7% ‡
Prison 14.7% ‡
Addiction services 17.7% ‡
Other 1.7% ‡
Distribution of PWID HCV tests
General 38.4% ‡
Prison 11.5% ‡
Addiction services 29.4% ‡
Other 20.7% ‡
*PropPWID 5 uninfected PWID utility value for age 15-19/uninfected ex-PWID utility for age 15-19.
†PPI 5 Hospital and Community Health Services Pay and Prices Index inﬂation factor from 03/04 to 13/14 (1.29).
‡Health Protection Agency unpublished data from the 2010 Sentinel Surveillance.
§Used to calculate an average weighted treatment cost, SVR, and treatment duration.
#Includes assessment, pretest discussion, test, posttest results, and enzyme-linked immunosorbent assay. Includes additional assessment
time in prison (20 minutes with nurse).
Abbreviations: CC, compensated cirrhosis; DC, decompensated cirrhosis; HCC, hepatocellular carcinoma; LT, liver transplant; NHS,
National Health Service; PCR, polymerase chain reaction; PR, pegylated interferon and ribavirin; SOF, sofosbuvir.
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threshold of £13,000, in line with a recent estimate of
where the UK WTP should lie.(10) Cost-effectiveness
acceptability curves are presented. Multiple one-way
sensitivity analyses were undertaken.
PARAMETERIZATION
HCV Prevalence and Cascade of Care
We modeled a scenario with a 35% baseline HCV
chronic prevalence among PWID (approximately 45%
antibody prevalence among PWID as found in the
United Kingdom,(11) assuming 26% spontaneously
clear the virus(12)). Based on differential incarceration
rates by age, this results in a mean ﬁtted HCV chronic
prevalence among PWID of 35% in the community
and 34% in prison and an HCV incidence of 8.8 per
100 person-years (95% conﬁdence interval [CI] 5.9-
13.4 per 100 person-years) in the community and 8.3
per 100 person-years (95% CI 5.8-12.7 per 100 per-
son-years) in prison. We assumed HCV prevalence
among PWID is at steady state based on the stable
prevalence exhibited among PWID in contact with
drugs services from 2003 through 2013.(13) We
assumed that 50% of PWID(5) and 30% of ex-
PWID(14) were diagnosed initially in 2014. Setting-
speciﬁc testing rates in prison and the community for
PWID and ex-PWID have been estimated(3,4); see the
Supporting Information for more details on commu-
nity testing and cascade of care assumptions. Overall,
we estimated 6% of prison entrants tested per year,
consistent with reported testing rates prior to the intro-
duction of opt-out testing (6% in 2013(5)). Of those
tested, 15% are HCV antibody-positive. A recent
UK study reported a 56% referral rate from testing
services to specialist care in prison.(15) The time from
testing to treatment initiation in prison is unknown;
estimated time to referral in prison is 4 weeks,(6) so we
assumed treatment initiation within 2 months of diag-
nosis in prison. Among a national survey across Eng-
lish prisons in 2012, 28% of patients referred to
specialist care commenced treatment in the same
year,(7) but it is unknown what proportion were
PWID. Hence, we assumed 25% of ex-PWID com-
mence treatment within 2 months of diagnosis in
prison. Community PWID treatment rates in the
United Kingdom are low (<25 per 1000 PWID annu-
ally), and due to the short sentences for PWID (4
months) and challenges with continuity of care after
transfer or release, it is likely prison treatment rates are
similarly low. Hence, we assumed that 2.5% (sampled
from 0%-5%) of those PWID referred to specialist
care from prison commence treatment within 2
months at baseline.
Incarceration Parameters
The model was parameterized and calibrated to
detailed UK data on incarceration patterns among
PWID and the general population. We calibrated the
model to 10,000 prisoners incarcerated at a given time
(approximately 5,000,000 total individuals based on a
0.2% incarceration prevalence among the general pop-
ulation(16,17)). See Martin et al.(3,4) and the Supporting
Information for more details.
HCV DISEASE PROGRESSION
AND HEALTH UTILITIES
Parameters for HCV disease progression and health
utilities were taken from published UK economic evalua-
tions(3,18,19) and recent data on progression from cirrhosis
after SVR.(20,21) These assumptions result in a mean 12%
progression to cirrhosis within 20 years of infection with-
out treatment, consistent with published estimates.(22)
COSTS
Costs related to HCV disease stages, HCV testing,
and HCV treatment were taken from previous UK
economic evaluations(3,19,23) and the British National
Formulary.(24) We assumed individuals with undiag-
nosed HCV would not incur health care costs until
progressing to decompensated cirrhosis. Costs were
inﬂated to 2014 British pounds using the Health and
Community Hospital Service pay and prices index.
Although we include costs for testing, we do not
include additional costs for the testing scale-up as no
additional funding was provided to the pilot prisons of
the opt-out program.
SENSITIVITY ANALYSES
We performed matched univariate sensitivity analy-
ses on the following parameters: discount rate (0% and
6% compared to 3.5% at base case), IFN-free SVR
(90% compared to 95% at base case), IFN-free treat-
ment duration (8 weeks compared to 8-12 weeks at
base case), DAA drug cost (25% reduction compared
to base case), proportion referred for treatment (100%
versus 56% at base case), time horizon (50 compared
to 100 years at base case), yield (30% reduction com-
pared to 0% at base case), and no prevention beneﬁt
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for 2.5% and 10% referred PWID treated scenarios
(2.5% referred PWID treated and prevention beneﬁt
included in base case).
Results
DOUBLING OF HCV TESTING
IN PRISON WITH STATUS
QUO TREATMENTS
Doubling testing in prison and providing status quo
HCV treatments results in approximately 2400 HCV
tests annually per 10,000 prisoners (19,500 entrants),
of which a mean of 353 are HCV antibody-positive,
261 are HCV RNA1, 146 are referred to treatment,
and 21 are initiated onto treatment. Despite assuming
a mean SVR of 87%, due to treatment interruption
and assuming no continuity of care on release, the
mean effective SVR is 40% (95% CI 38-46). The
intervention results in mean incremental costs of
£8,362,599 (95% CI £5,021,130-13,747,661) per
10,000 prisoners and mean incremental QALYs
gained of 421.27 (95% CI 172.93-789.53) compared
to status quo testing and treatment (Table 2). This
strategy results in a mean ICER of £19,851 per
QALY gained and is 45% and 85% likely to be cost-
effective at a £20,000 or £30,000 per QALY gained
WTP threshold, respectively (Fig. 1A).
DOUBLING OF HCV TESTING
IN PRISON WITH 8-WEEK TO
12-WEEK IFN-FREE DAAS WITH
95% SVR IN PRISON
If HCV testing in prison is doubled and a switch to
8-week to 12-week IFN-free DAA therapy is provided
with 95% SVR in prison, costs increase due to provi-
sion of DAA therapy for all genotypes (mean incre-
mental costs £2,584,159, 95% CI £872,364-
6,078,955, per 10,000 prisoners compared to doubled
testing with status quo treatments), but QALYs are
gained (171.25, 95% CI 46.89-396.74) due to a com-
bination of increased SVR and shorter treatment dura-
tion for genotype 2 and 3 patients without cirrhosis
from 24 to 12 weeks (Table 2). Overall, this results in
a mean ICER of £15,090 per QALY gained compared
to doubled testing and status quo treatments and is
84% and 96% likely to be cost-effective at a £20,000 or
£30,000 per QALY gained WTP threshold, respec-
tively (Fig. 1B). Despite assuming a mean SVR of
95%, the mean effective SVR is 46% (95% CI 43-
53%). In this scenario, roughly half the beneﬁt is due
to shortening treatment; with only a shortening of
treatment (but SVR rates equal to the status quo sce-
nario) the intervention gains 79.67 QALYs (95% CI
22.8-177.21).
DOUBLING HCV TESTING
WITH INCREASED PWID HCV
TREATMENT RATES IN PRISON
Increasing PWID treatment rates after referral in
prison results in signiﬁcant increases in the cost-
effectiveness of doubled testing using current treat-
ments (Fig. 2A) or if 8-week to 12-week IFN-free
DAAs are introduced (Fig. 2B). If 10% of PWID are
treated after referral in prison, the ICERs for both
treatment interventions drop below £13,000/QALY
gained (£12,691/QALY with current treatments and
£6461/QALY gained with 8-week to 12-week IFN-
free DAAs). In this scenario, doubling testing with
current treatments is 47% and 93% likely to be cost-
effective under £13,000 and £20,000 WTP thresh-
olds, respectively, and is 99% likely to be cost-
effective under a £13,000 WTP threshold with 8-
TABLE 2. Cost-Effectiveness Results
Mean incremental
costs (£) per
10,000 prisoners*
(95% CI)
Mean incremental
QALYs per
10,000 prisoners*
(95% CI)
Mean ICER
(£ per QALY gained)
Double testing and provide status quo treatment 8,362,599† (5,021,130-13,747,661) 421.27† (172.93-789.53) 19,851†
Double testing and provide 12-week
IFN-free DAA therapy in prison
2,584,159‡ (872,364-6,078,955) 171.25‡ (46.89-396.74) 15,090‡
*We calibrated the model to 10,000 prisoners incarcerated at a given time (approximately 5,000,000 total individuals based on a 0.2%
incarceration prevalence among the general population(15,16)) and tracked individuals both in the community and those who cycle in/
out of prison.
†Compared to the status quo testing and treatment scenario.
‡Compared to the double testing and status quo treatment scenario.
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week to 12-week IFN-free DAAs. If 25% of PWID
are treated after referral, the ICER drops to below
£8000 and £4000 per QALY gained for the status
quo treatment scenarios and 8-week to 12-week
IFN-free DAA scenarios, respectively.
SENSITIVITY ANALYSIS
When performing a univariate sensitivity analysis on
the mean ICER with status quo treatments (Fig. 3A),
we found that enhancements in the cascade of care
increased cost-effectiveness and that population pre-
vention beneﬁts increase as treatment rates for PWID
increase. If 100% of patients were referred in prison
(56% at base case), the mean ICER dropped to just
over £15,000/QALY. Turning off the prevention ben-
eﬁt at base case led to marginal reductions in cost-
effectiveness because PWID treatment rates were very
low at baseline, so little prevention beneﬁt accrued
(mean ICER £22,051/QALY gained versus £19,851/
QALY gained with prevention beneﬁts). However,
the prevention beneﬁt substantially increases with
increased treatment rates; treating 10% of referred
PWID in prison leads to a mean ICER of £20,064/
QALY gained without prevention beneﬁts but is
highly cost-effective with prevention beneﬁts included
(mean ICER £12,495/QALY gained, Fig. 3A).
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FIG. 1. Cost-effectiveness acceptability curves for doubled HCV
case-ﬁnding in prison combined with (A) status quo treatments
and (B) 8-week to 12-week IFN-free DAAs in prison. Incre-
mental comparisons shown are (A) doubled HCV case-ﬁnding in
prison combined with status quo treatments compared to status
quo testing/treatment and (B) doubled HCV case-ﬁnding com-
bined with 8-week to 12-week IFN-free DAAs in prison com-
pared to doubled case-ﬁnding with status quo treatments.
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FIG. 2. Changes in mean ICER with increased PWID treat-
ment rates in prison (2.5%-25% after referral). Base-case analysis
assumes a mean of 2.5% PWID treated after referral in prison.
(A) Doubled testing with status quo treatments compared to
status quo testing/treatment. (B) Double testing with 8-week to
12-week IFN-free DAAs compared to doubled testing with sta-
tus quo treatments.
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For all other analyses, the only analysis which
increased the ICER above £30,000/QALY was if the
doubled testing was associated with a 30% drop in
yield (mean ICER £32,893; no change in base case).
Shortening the time horizon (50 years compared to
100 years at base case) and increasing the discount rate
(6% compared to 3.5% at base case) increased the
mean ICER, but it remained below £30,000/QALY
(Fig. 3A). Reducing the discount rate to 0% (3.5%/
year at base case) and lowering the cost of DAAs in
prison by 10% or 25% reduced the ICER (Fig. 3A).
Qualitative results were similar with the sensitivity
analysis on the mean ICER using 8-week to 12-week
IFN-free treatments; all scenarios led to ICERs below
£30,000/QALY (Fig. 3B). We additionally found that
if IFN-free SVR was 90% (instead of 95%), the ICER
remained below £20,000/QALY (£19,325/QALY).
When switching to IFN-free DAAs, the ICER is sen-
sitive to DAA drug cost; if the price of IFN-free
DAAs is reduced by 10%, the mean ICER drops to
below £13,000/QALY gained. If 8-week IFN-free
therapies for all genotypes are provided in prison, the
mean ICER dropped to £6180/QALY. Although this
scenario resulted in a slightly higher effective SVR due
to greater treatment completion (mean effective SVR
48% overall versus 46% with 8-week to 12-week treat-
ments), the main improvement in cost-effectiveness
was the result of reduced cost of treatment due to
shorter durations.
EPIDEMIC IMPACT
Our model shows that baseline/existing levels of
HCV treatment for PWID in prison and the commu-
nity are unlikely to result in observable changes in
HCV chronic prevalence or incidence among PWID
in prison in the next 50 years (<9% relative reduction,
Supporting Information). Negligible additional impact
on HCV chronic prevalence or incidence among
PWID in prison (<1% relative difference from base-
line) is seen with doubled HCV testing in prison due
to the low baseline treatment rates for PWID in
prison. Similarly, doubled prison testing would only
further reduce the cumulative incidence of hepatocellu-
lar carcinoma, liver transplant, or HCV-related deaths
among the entire population by an additional 1% over
the next 50 years. Even with doubled HCV testing in
prison and a switch to 8-week to 12-week DAAs in
prison, combined with a scale-up of HCV treatment
such that 25% of PWID are treated after referral in
prison, the modest reductions (12% relative reduction)
in chronic prevalence or incidence occur among
PWID in prison in 50 years. This is due to the low
effective treatment rates for PWID given the gaps in
the cascade of care from testing to SVR.
Discussion
We found that increased HCV testing in prison in
England—such as that based on an opt-out interven-
tion, which doubled HCV testing in pilot prisons—is
borderline cost-effective with current treatments com-
pared to status quo voluntary risk-based testing and is
likely to be cost-effective if shorter-course IFN-free
DAA therapy is used in prison under a £20,000 WTP
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FIG. 3. One-way sensitivity analyses on mean ICERs. Black
horizontal line denotes the base case ICER. (A) Doubled testing
with status quo treatments compared to status quo testing/treat-
ment. (B) Double testing with 8-week to 12-week IFN-free
DAAs compared to doubled testing with status quo treatments.
Abbreviations: BC, base case; GBP, British pounds; prev ben,
prevention beneﬁt.
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threshold. Increased HCV testing could be highly
cost-effective (mean ICER <£13,000/QALY gained)
if the cascade of care is improved through increasing
PWID treatment rates. For example, if >10% PWID
are treated after referral in prison (four times higher
than the 2.5% base case), then doubled testing in
prison is estimated to have a mean ICER of
<£13,000/QALY gained. Cost-effectiveness is inﬂu-
enced by population prevention beneﬁts—averting sec-
ondary infections in the community—and DAA costs.
Without prevention beneﬁts, HCV testing is above
the £20,000 WTP, whereas increasing prevention ben-
eﬁt (through increasing PWID treatment rates) and
decreasing costs could achieve cost-effectiveness below
£13,000 WTP. However, even with 8-week treat-
ments, SVR may be compromised without ensuring
continuity of care or targeting treatment to people with
slightly longer than average sentences.
STRENGTHS AND LIMITATIONS
A key strength of our model is the dynamic trans-
mission component, such that cost-effectiveness
includes both individual-level beneﬁts (on prevention
of disease progression) and population-level beneﬁts
(on prevention of HCV transmission among PWID).
However, there are a number of limitations due to a
lack of data on key parameters.
First, one of the main drivers of cost-effectiveness is
the fall-off from different stages in the cascade of care,
such as referral and treatment rates. Unfortunately,
limited data are available on these rates across the
prison system and no data stratiﬁed by injecting risk
status.(25) Our referral rate in prison is based on empir-
ical evidence from three prisons but may not be repre-
sentative nationally, though we do include wide
uncertainty. Furthermore, the model allocates treat-
ment randomly, which can compromise effective SVR.
Although in some prisons patients are selected for
treatment in part based on duration of stay, it is unclear
how widespread this practice is and what implications
this has on PWID treatment rates (which, if reduced,
will adversely affect cost-effectiveness but if treatment
completion is increased, then cost-effectiveness will
improve substantially). Additionally, there is a lack of
data on disease stage among prisoners, which may
impact treatment eligibility and treatment rates with
IFN-free DAAs. Due to cost considerations, US and
European guidelines recommend prioritizing HCV
treatment for those with advanced liver disease (F3/
F4), and recent European guidelines also recommend
treating people at risk of transmission such as
PWID(26) irrespective of disease stage. However, it
seems more likely that the United Kingdom and other
countries in Europe will prioritize treatment based on
disease stage.(27) HCV patients within prisons (espe-
cially PWID) are generally younger with less advanced
disease and thus could be less likely to receive IFN-free
DAA therapies. Clinicians treating such cohorts
within and outside prisons may be inclined to defer
therapy in the hope that they may become eligible for
safer, better-tolerated regimes as the guidelines are
revised with a decline in costs over time. Also, cirrhosis
assessment requires additional investigations, which
may prolong assessment time and reduce time for
treatment. Indeed, despite relatively short reported
times to referral from the phase 1 “pathﬁnder prisons”
(<4 weeks), the standard against which prison per-
formance is measured is 18 weeks, so if delays to refer-
ral and during assessment occur, this could further
limit the number of PWID who can be successfully
treated in prison. Therefore, shorter IFN-free DAA
therapy may not necessarily translate into greater access
to treatment within prison, particularly among PWID,
in the absence of continuity of care arrangements with
the community.
Second, we used preliminary data from the opt-out
pilot program to inform our assumptions surrounding
impact on testing rates and, therefore, model a dou-
bling of HCV testing rates as achieved in these pilot
prisons, but the impact when fully implemented is
unclear. However, other interventions to increase
HCV testing in UK prisons have been unsuccessful.(28)
Third, there is uncertainty regarding SVR rates with
IFN-free DAA therapies among PWID and prisoners.
Systematic reviews have shown comparable SVR with
IFN-based therapies among PWID and noninjecting
populations, and preliminary trials with IFN-free
DAAs among PWID on opiate substitution therapy
indicate no difference in SVR compared to noninjec-
tors. Nevertheless, we show that IFN-free DAAs in
prison are likely cost-effective even with lower SVR
rates (90%) and that an important driver will be
“effective SVR” related to treatment completion.
Fourth, due to a lack of data, we assumed no conti-
nuity of treatment between prison and community
such that those who are released while on treatment or
in referral for treatment are assumed lost to follow-up
and require retesting and reengagement. Providing
effective continuity of care should increase the propor-
tion successfully treated after diagnosis (whether in
prison or the community) and could likely increase
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cost-effectiveness.(3) Currently, some patients diag-
nosed in prison choose to defer treatment until they
return to the community for such reasons such as fear
of stigma within prison and the desire for a family/peer
support network during treatment. Therefore, cost-
effectiveness and public health impact will be affected
by how well continuity of care is ensured across custo-
dial and community settings, and efforts should be
made to strengthen these transitions.
Fifth, due to a lack of data on HCV prevalence
among PWID in prison, we modeled a 35% chronic
prevalence among all PWID,(11) which corresponds to
a similar prevalence among incarcerated PWID based
on the age distribution of incarceration rates among
PWID. However, if HCV prevalence/incidence
among PWID in prison is lower than that in the com-
munity, HCV treatment in prison may have more pre-
vention beneﬁt and may be more cost-effective.
Additionally, we assumed proportional mixing by age
among PWID in prison (and the community) due to a
lack of data to suggest otherwise. However, if PWID
mix partially assortatively by age in prison, such that
young PWID mix more with young PWID, this could
lead to a lower HCV chronic prevalence among
PWID in prison than we modeled and, consequently,
greater treatment as prevention beneﬁts.
Sixth, we assumed no improvement in ﬁbrosis
score upon successful treatment with DAAs, despite
evidence that ﬁbrosis regression may occur in a por-
tion of patients after DAA therapy, although the par-
ticular patients who beneﬁt, the degree of beneﬁt,
and the timing of improvement are uncertain.(29,30)
However, our analysis found HCV testing and DAA
therapy highly likely to be cost-effective, and includ-
ing improvement in ﬁbrosis would increase cost-
effectiveness further.
Seventh, we assumed no behavior change after
HCV testing or treatment due to a lack of strong evi-
dence in this area. Two small studies have found
decreases in injecting risk behavior with a positive
HCV diagnosis(31,32); however, a recent large pro-
spective pooled analysis among 829 PWID in Can-
ada, the United States, The Netherlands, and
Australia found no evidence of injecting risk behavior
change for PWID after a positive or negative HCV
diagnosis.(33) If HCV testing reduces risk among
those with or without HCV, this would further
improve any case-ﬁnding intervention. Additionally,
it is possible individuals will reduce their risk follow-
ing successful treatment, which would also increase
the cost-effectiveness of HCV treatment.
COMPARISON WITH OTHER
STUDIES
Two previous IFN-based studies using static models
(ignoring prevention beneﬁt in the community) sug-
gested that HCV testing in UK prisons was unlikely to
be cost-effective.(34,35) Our previous analysis found that
increased HCV testing in English prisons was unlikely
to be cost-effective (ICER £60,000/QALY gained)
with IFN/RBV treatment due to a combination of
short incarceration durations (4/8 months for PWID/
non-PWID, respectively), long treatment durations (24-
48 weeks), and a lack of continuity of care between
prison and the community.(3) In contrast, our current
analysis suggests that HCV case-ﬁnding in English pris-
ons is borderline cost-effective with currently available
therapies and more likely to be cost-effective with highly
effective short-course IFN-free DAA therapies. Our
study supports a recent dynamic modeling study in the
United States which found that opt-out testing in prison
with DAAs is likely cost-effective, but their study
assumed much higher rates of testing uptake (90% com-
pared to 12% in our study based on pilot data) as well as
behavior change after diagnosis and treatment (which we
did not assume).(36)
IMPLICATIONS
Prisons can be an important contributor to blood-
borne virus risk for PWID(37) but can also play a role
in public health prevention. Prisoners should receive
the same standard of care as people in the community;
however, interventions do need to be cost-effective.
HCV case-ﬁnding among PWID in the community is
cost-effective, but because continuity of care could not
be guaranteed between prison and the community, it
was unlikely to be cost-effective in prison. We show
that the arrival of shorter (and more effective) HCV
treatment regimens, which means that more prisoners
can complete treatment prior to release, alters the cost-
effectiveness decision. Treatment uptake in prison, as
well as IFN-free DAA therapy cost, now are the main
drivers of cost-effectiveness of HCV case-ﬁnding. In
addition, cost-effectiveness is predicated on the
“prevention beneﬁt” of reducing HCV transmission in
the community through successfully treating PWID,
which requires empirical demonstration. Further,
enhanced data collection of the cascade of care in
prison, as will be achieved through the new Health and
Justice Information Service, will allow for better
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monitoring and evaluation of prison HCV testing and
treatment programs in the future.
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